CTSO
Cytosorbents·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 3
Bearish signal 0
Ample Liquidity
High Gross Profit Margin
Revenue Beats Expectation
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About CTSO
Cytosorbents Corporation
A leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification
Healthcare Equipment and Supplies
04/25/2002
12/23/2014
NASDAQ Stock Exchange
149
12-31
Common stock
305 College Road East
, Princeton
, New Jersey 08540
--
Cytosorbents Corporation was incorporated in Nevada on April 25, 2002. The company is an intensive immunotherapy company in intensive care that uses blood purification to regulate inflammation, with the goal of preventing or treating life-threatening multiple organ failure. The technology is based on biocompatible, highly porous polymer adsorbent beads that can extract unwanted substances in blood and other body fluids. The technology is protected by 32 US patents.
Earnings Call
Q3/2025
Estimate EPS-0.05
Actual EPS-0.04
Estimate Revenue10.02M
Actual Revenue9.50M
Cytosorbents Q3 2025 Earnings Call: Contradictions Emerge on Germany Restructuring, Sales Growth, and Regulatory Hurdles
Nov 16,2025 08:02
Earnings Decrypt
Earnings Decrypt
Q1/2025
Estimate EPS--
Actual EPS-0.06
Estimate Revenue9.01M
Actual Revenue8.73M
Cytosorbents Q1 2025: Navigating Contradictions in FDA Strategies, Profitability, and European Growth
May 20,2025 07:49
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
CTSO has released its 2025 Q3 earnings. EPS was reported at -0.04, versus the expected -0.05, beating expectations. The chart below visualizes how CTSO has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
CTSO has released its 2025 Q3 earnings report, with revenue of 9.48M, reflecting a YoY change of 10.12%, and net profit of -3.17M, showing a YoY change of -14.52%. The Sankey diagram below clearly presents CTSO's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
